Physician profile
Jodi Myers
NPI 1942588793
$11,681.76
in general payments reported to CMS, 2019-2025
21 companies · $7,076 in 2025
The $7,076 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $787 · 2022: $994 · 2023: $1,909 · 2024: $915 · 2025: $7,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,200 · Food and Beverage: $1,400 · Honoraria: $1,000 · Travel and Lodging: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,200.00 |
| Food and Beverage | $1,400.44 |
| Honoraria | $1,000.00 |
| Travel and Lodging | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Altathera Pharmaceuticals LLC | $8,670.07 | 2023-2025 | Sotalol Hydrochloride |
| Novartis Pharmaceuticals Corporation | $774.69 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $528.06 | 2021-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $422.77 | 2021-2023 | Eliquis, Camzyos |
| Abiomed | $397.69 | 2024-2025 | Impella |
| Cvrx, INC. | $165.94 | 2022 | |
| Amgen INC. | $99.66 | 2021-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.28 | 2022-2023 | Jardiance |
| Medtronic, INC. | $94.31 | 2021 | |
| Alnylam Pharmaceuticals INC. | $82.48 | 2022-2024 | Onpattro |
| Abbott Laboratories | $56.48 | 2021-2025 | Jot Dx |
| Pfizer INC. | $51.85 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.91 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $36.90 | 2021-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $33.69 | 2024 | Arcalyst |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, Ltd. | $30.47 | 2021-2022 | |
| Edwards Lifesciences Corporation | $23.04 | 2022 | |
| Atricure, INC. | $22.49 | 2024 | |
| Merck Sharp & Dohme LLC | $21.20 | 2022 | |
| Genzyme Corporation | $19.47 | 2022 | |
| Esperion Therapeutics, INC. | $15.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jodi Myers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.